A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia.
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Data on the effectiveness of antipsychotics in the early phase of schizophrenia are limited. The authors examined the risk of rehospitalization and drug discontinuation in a nationwide cohort of 2,588 consecutive patients hospitalized for the first time with a diagnosis of schizophrenia between 2000 and 2007 in Finland. METHOD: The authors linked national databases of hospitalization, mortality, and antipsychotic prescriptions and computed hazard ratios, adjusting for the effects of sociodemographic and clinical variables, the temporal sequence of the antipsychotics used, and the choice of the initial antipsychotic for each patient. RESULTS: Of 2,588 patients, 1,507 (58.2%) collected a prescription for an antipsychotic during the first 30 days after hospital discharge, and 1,182 (45.7%, 95% confidence interval [CI]=43.7-47.6) continued their initial treatment for 30 days or longer. In a pairwise comparison between depot injections and their equivalent oral formulations, the risk of rehospitalization for patients receiving depot medications was about one-third of that for patients receiving oral medications (adjusted hazard ratio=0.36, 95% CI=0.17-0.75). Compared with oral risperidone, clozapine (adjusted hazard ratio=0.48, 95% CI=0.31-0.76) and olanzapine (adjusted hazard ratio=0.54, 95% CI=0.40-0.73) were each associated with a significantly lower rehospitalization risk. Use of any antipsychotic compared with no antipsychotic was associated with lower mortality (adjusted hazard ratio=0.45, 95% CI=0.31-0.67). CONCLUSIONS: In Finland, only a minority of patients adhere to their initial antipsychotic during the first 60 days after discharge from their first hospitalization for schizophrenia. Use of depot antipsychotics was associated with a significantly lower risk of rehospitalization than use of oral formulations of the same compounds. Among oral antipsychotics, clozapine and olanzapine were associated with more favorable outcomes. Use of any antipsychotic was associated with lower mortality.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
Lacro, J. P., Dunn, L. B., Dolder, C. R., Leckband, S. G., & Jeste, D. V. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n1007 · Cited by 1,383 · cited 2×
“2% of patients did not regularly take medication as prescribed (8), that prescription completion rates ranged from 28% to 85% (9), and that irregular medication use rates ranged from 31% to 62% (9).”
BackgroundTiihonen, J., Lönnqvist, J., Wahlbeck, K., Klaukka, T., Niskanen, L., Tanskanen, A., & Haukka, J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60742-x · Cited by 1,354
Self-citationRobinson, D., Woerner, M. G., Alvir, J. M. J., Bilder, R., Goldman, R., Geisler, S., Koreen, A., Sheitman, B., Chakos, M., Mayerhoff, D., et al. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.3.241 · Cited by 1,327
Kahn, R. S., Fleischhacker, W. W., Boter, H., Davidson, M., Vergouwe, Y., Keet, I. P., Gheorghe, M. D., Rybakowski, J. K., Galderisi, S., Libiger, J., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60486-9 · Cited by 1,088
McEvoy, J. P., Lieberman, J. A., Stroup, T. S., Davis, S. M., Meltzer, H. Y., Rosenheck, R. A., Swartz, M. S., Perkins, D. O., Keefe, R. S. E., Davis, C. E., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.4.600 · Cited by 1,018
The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements
Buchanan, R. W., Kreyenbuhl, J., Kelly, D. L., Noel, J. M., Boggs, D. L., Fischer, B. A., Himelhoch, S., Fang, B., Peterson, E., Aquino, P. R., et al. (2010) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp116 · Cited by 907
Compliance With Medication Regimens for Mental and Physical Disorders
Cramer, J. A., & Rosenheck, R. (1998) · Psychiatric Services · doi:10.1176/ps.49.2.196 · Cited by 725
Adverse Effects of Atypical Antipsychotics: Differential Risk and Clinical Implications
Haddad, P. M., & Sharma, S. G. (2007) · CNS Drugs · doi:10.2165/00023210-200721110-00004 · Cited by 456
Self-citationMedication adherence of individuals with a first episode of psychosis
Coldham, E. L., Addington, J., & Addington, D. (2002) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.2002.02437.x · Cited by 413
Research works printed but not linked: 4
- National Institute for Health and Clinical Excellence (NICE), 2009, Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Adults in Primary and Secondary Care (Update), Final Version (NICE Clinical Guideline 82)
- Young JL, 1986, Bull Am Acad Psychiatry Law, 14, 105
- Young JL, 1999, J Am Acad Psychiatry Law, 27, 426
- 10.1176/ps.2007.58.4.482 · doi:10.1176/ps.2007.58.4.482 · Paper page
Cited by
Items 501–600 of 618
Taylor, D. M. (2012) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12018 · Cited by 2
Weiden, P. J. (2013) · The Canadian Journal of Psychiatry · doi:10.1177/088740341305805s01 · Cited by 2
Zusammenhänge zwischen funktionellen Psychosen und Kriminalität/Gewalttätigkeit
Schanda, H., & Stompe, T. (2023) · Springer eBooks · doi:10.1007/978-3-662-64465-2_3 · Cited by 2
Hietala, E., Solismaa, A., Lähteenvuo, M., Ahola‐Olli, A., Häkkinen, K., Suokas, K., Isometsä, E. T., Suvisaari, J., Kieseppä, T., Torniainen‐Holm, M., et al. (2025) · Acta Neuropsychiatrica · doi:10.1017/neu.2025.11 · Cited by 1
Self-citationSzmulewicz, A., Martínez‐Alés, G., Logan, R. W., Joober, R., Ferrara, M., Kelly, C., Fredrikson, D. H., Thorpe, L. E., Conderino, S. E., Díaz‐Caneja, C. M., et al. (2025) · Nature Mental Health · doi:10.1038/s44220-025-00407-5 · Cited by 3
Khandker, R. K., Mohit, B., Fonseca, E., Fleming, S., Tan, M. S., Quan, W., LeMasters, T., & Schmier, J. K. (2025) · Schizophrenia Research · doi:10.1016/j.schres.2025.07.017 · Cited by 1
The duration of active psychosis and relationship with early psychosis outcomes
Crowley, P., Boland, F., Thompson, A., McGorry, P. D., O'Donoghue, B. N., & Lyne, J. (2026) · Schizophrenia Research · doi:10.1016/j.schres.2026.03.014 · Cited by 1
Çallı, S. Y., Fidan, Y. S., Kızılsert, A., İzci, F., & Üçok, A. (2026) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000002183 · Cited by 1
A Post-Authorisation Safety Survey Evaluating Risperidone Long-Acting Injectable in Romania
£ia, I. M., Paunescu, R., & Ciungu, R. (2015) · Journal of psychiatry · doi:10.4172/2378-5756.1000301 · Cited by 1
Depotantipsychotika: Überblick und Hinweise für die Praxis
Köhler, S., Heinz, A., & Sterzer, P. (2013) · Der Nervenarzt · doi:10.1007/s00115-013-3842-4 · Cited by 1
Stroup, T. S. (2012) · Revista de Psiquiatría y Salud Mental · doi:10.1016/j.rpsm.2012.06.003 · Cited by 1
Ciudad, A., Anand, E., Berggren, L., Casillas, M., Schacht, A., & Perrin, E. (2013) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s50635 · Cited by 4
Should we listen and talk more to our patients?
Naber, D., & Lambert, M. (2013) · World Psychiatry · doi:10.1002/wps.20066 · Cited by 1
Kivimies, K., Repo‐Tiihonen, E., Kautiainen, H., & Tiihonen, J. (2013) · Nordic Journal of Psychiatry · doi:10.3109/08039488.2013.830770 · Cited by 3
Self-citationRuiu, S., Casu, M. A., Casu, G., Piras, S., & Marchese, G. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.690397 · Cited by 3
Chancen und Kontroversen von Depotantipsychotika in der Behandlung von Patienten mit Schizophrenie
Breit, S., & Hasler, G. (2015) · Der Nervenarzt · doi:10.1007/s00115-015-0021-9 · Cited by 2
Pharmakotherapie der therapieresistenten Schizophrenie
Huhn, M., Samara, M. T., & Leucht, S. (2019) · PSYCH up2date · doi:10.1055/a-0801-2103 · Cited by 1
Freudenreich, O. (2019) · Current clinical psychiatry · doi:10.1007/978-3-030-29450-2_11 · Cited by 1
Jalbert, J. J., Rossignol, M., Astruc, B., Bayle, F., Nordon, C., Avouac, B. P., Rouillon, F., Abenhaim, L. L., & Grimaldi‐Bensouda, L. (2017) · Journal of Population Therapeutics and Clinical Pharmacology · doi:10.22374/1710-6222.24.2.7 · Cited by 1
Illness Insight and Antipsychotic Medication Adherence
Freudenreich, O. (2019) · Current clinical psychiatry · doi:10.1007/978-3-030-29450-2_31 · Cited by 1
McCutcheon, R. A., Kaar, S. J., & Howes, O. D. (2020) · Cambridge University Press eBooks · doi:10.1017/9781911623465.011 · Cited by 1
Such, P., Olivares, J. M., Arias, L., Berg, M. T., & Madera‐McDonough, J. (2021) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s303292 · Cited by 1
Depot-Antipsychotika in der Rezidivprophylaxe
(2014) · psychopraxis neuropraxis · doi:10.1007/s00739-014-0218-x · Cited by 1
Drake, R. (2020) · Cambridge University Press eBooks · doi:10.1017/9781911623465.012 · Cited by 1
Peters, E. M., Shamloo, A., Lodhi, R. J., Marcoux, G., Jackson, K., Halayka, S., & Balbuena, L. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.917361 · Cited by 2
Psychological treatment outcomes for outpatients in a clinical context
Lundkvist, J. E., Georgsson, K., Carlbring, P., Borg, E., Ramnerö, J., Johansson, R., Ljungberg, T., & Anderbro, T. (2023) · Nordic Psychology · doi:10.1080/19012276.2023.2206540 · Cited by 1
Akbari, A., Nia, H. S., Zarghami, M., Azari, P., Hendouei, F., & Hendouei, N. (2023) · Iranian Journal of Psychiatry and Behavioral Sciences · doi:10.5812/ijpbs-133703 · Cited by 1
Postinjection Syndrome After Paliperidone?
Žmitek, A., & Jovan, Z. (2023) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001742 · Cited by 1
Chapter 29. Risperidone and Paliperidone
Lopez, L. V., Hill, M. B., & GOFF, D. C. (2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375523.as29 · Cited by 1
Koch, T., von Peter, S., Weinmann, S., & Ruiz‐Pérez, G. (2025) · Psychiatry Research · doi:10.1016/j.psychres.2025.116685 · Cited by 1
Theodoros, T., Taylor, M., Huang, H. C.-H., Wang, N., & Motamarri, B. (2018) · Australasian Psychiatry · doi:10.1177/1039856218758559 · Cited by 1
Self-citationAttard, A., Wakelam, J., Broyd, J. G., Taylor, D. M., & Hafferty, J. D. (2022) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253221113093 · Cited by 1
Antipsychotic treatment of schizophrenia. We can do better
Bruijnzeel, D. M., & Tandon, R. (2017) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2017.07.027 · Cited by 1
Dr Correll and Colleagues Reply
Correll, C. U., Citrome, L., Haddad, P. M., Lauriello, J., Olfson, M., & Kane, J. M. (2017) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.16lr11402a · Cited by 1
Self-citationNovel long-acting and extended-release formulations of antipsychotic drugs
Alphs, L. D. (2012) · doi:10.2217/ebo.11.301 · Cited by 1
Tiihonen, J. (2018) · Schizophrenia Research · doi:10.1016/j.schres.2018.06.035 · Cited by 2
Self-citationKhan, Z., Varvari, I., Mancini, V., Zauchenberger, C., Kantor, S., Fanshawe, J., Musiiwa, S., Pledge, A., Pearce, B., Motte, S. D. D. L., et al. (2025) · medRxiv · doi:10.1101/2025.04.04.25325236 · Cited by 1
Schizophrenia and Related Psychoses
(2025) · Wiley eBooks · doi:10.1002/9781119870203.mpg001.pub2 · Cited by 2
Long-Term Pharmacological Management of Schizophrenia
Marder, S. R. (2014) · Springer eBooks · doi:10.1007/978-1-4939-0656-7_13
Stroup, T. S. (2012) · Revista de Psiquiatría y Salud Mental (English Edition) · doi:10.1016/j.rpsmen.2012.06.001
Correll, C. U. (2013) · European Psychiatry · doi:10.1016/s0924-9338(13)77494-7
Welches Langzeit-Antipsychotikum für welchen Schizophreniepatienten?
Dose, M. (2015) · DNP - Der Neurologe und Psychiater · doi:10.1007/s15202-015-0582-1
Olanzapine long-acting injection: insights from an early case series in the UK
McGlennon, D., & Bushe, C. (2012) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125312446395
Cognition, Adherence and Stigma in Schizophrenia
Brain, C. (2015)
Ragusa, M., Patriarca, S., Stratta, P., Collazzoni, A., & Rossi, A. (2015)
Psühhoosihaigele võimaldatud nüüdisaegne toetusravi toob kasu nii haigele kui ka ühiskonnale
Eino, K., & Saluveer, E. (2016) · Ajakirjad. Journals by UT · doi:10.15157/ea.v0i0.12631
TheEffectofRace-Ethnicityand GeographyonAdoptionofInnovations intheTreatmentofSchizophrenia
Horvitz-Lennon, M. V., Alegria, M. M., & Normand, S. T. (2012)
Are depot as effective as oral antipsychotics on first-episode psychosis?
Norte, C. O., & Aceituno, D. (2016) · Medwave · doi:10.5867/medwave.2016.6447
Treatment of Schizophrenia with Antipsychotic Medications
(2013) · WORLD SCIENTIFIC eBooks · doi:10.1142/9789814343664_0005
Do doctors agree on doses of antipsychotic medications?
Schill, J., & Olsson, H. (2016) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125316657796
Amodeo, G., Candiracci, C., Capecci, I., Filippis, S. D., Giuliani, S., Guerani, G., Tomasetti, C., Villari, V., & Fagiolini, A. M. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1244526
Highlights from the Latest Advances in Psychiatry meeting
David, F. (2017) · Prescriber · doi:10.1002/psb.1555
Mohr, P., Knytl, P., Voráčková, V., Bravermanová, A., & Melicher, T. (2017) · Psychiatrie pro praxi · doi:10.36290/psy.2017.003
Simplifying medication administration: From daily ingestion to monthly injection
Citrome, L. (2017) · International Journal of Clinical Practice · doi:10.1111/ijcp.13021
Quelle modalité de traitement médicamenteux ?
Giordana, B. (2019) · Elsevier eBooks · doi:10.1016/b978-2-294-76179-9.00010-3
Behandlung unter besonderen Bedingungen (Modul 4c)
Gäebel, W., Hasan, A., & Falkai, P. (2019) · Springer eBooks · doi:10.1007/978-3-662-59380-6_7
Pharmakotherapie und andere somatische Behandlungsverfahren (Modul 4a)
Gäebel, W., Hasan, A., & Falkai, P. (2019) · Springer eBooks · doi:10.1007/978-3-662-59380-6_5
What Is Suicidal Behavior, and Can It Be Prevented?
van Heeringen, K. (2018) · Cambridge University Press eBooks · doi:10.1017/9781316563205.002
“In my end is my beginning”: A Neurodevelopmental Perspective on Suicidal Behavior*
van Heeringen, K. (2018) · Cambridge University Press eBooks · doi:10.1017/9781316563205.008
I Predict, Therefore I Cannot Be: A Predictive Coding Account of Suicidal Behavior
van Heeringen, K. (2018) · Cambridge University Press eBooks · doi:10.1017/9781316563205.009
Predicting the Unpredictable: Neuroscience Contributions to Suicide Prediction
van Heeringen, K. (2018) · Cambridge University Press eBooks · doi:10.1017/9781316563205.010
The Dark Side of the Brain: Neuroscience Approaches to Suicidal Behavior
van Heeringen, K. (2018) · Cambridge University Press eBooks · doi:10.1017/9781316563205.004
Gattaz, W. F., Saracco-Álvarez, R. A., Daltio, C. S., van de Bilt, M. T., Ortegón, J. J., Villaseñor-Bayardo, S. J., Louzã, M. R., Elkis, H., Soares, B. G., Jaramillo, P. C., et al. (2020) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s233537
First-Episode & Early Psychosis in Transition-Age Youth
Faraji, P., Camp, C., Elberg, Z., & Usher, C. T. (2021) · Springer eBooks · doi:10.1007/978-3-030-62113-1_14
The Treatment of Suicide Risk: Neuroscience Aspects
van Heeringen, K. (2018) · Cambridge University Press eBooks · doi:10.1017/9781316563205.011
Images of the Suicidal Brain: Systems Neuroscience and Suicide
van Heeringen, K. (2018) · Cambridge University Press eBooks · doi:10.1017/9781316563205.007
I Think, Therefore I Do Not Want to Be: The Cognitive Neuroscience of Suicidal Behavior
van Heeringen, K. (2018) · Cambridge University Press eBooks · doi:10.1017/9781316563205.006
Meyer, M.-A., Colson, S., Rolland, A., Raphaël Gaillard, B., Guernion, T., & Plaze, M. (2021) · Revue Francophone Internationale de Recherche Infirmière · doi:10.1016/j.refiri.2021.100241
Cognition, Adherence and Stigma in Schizophrenia. The COAST study
Brain, C. (2015) · Gothenburg University Publications Electronic Archive (Gothenburg University) · Cited by 1
Laven, A., Bienentreu, S., Nick, B., Winkler, D., & Correll, C. U. (2021) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2021.10.448
(2018) · Cambridge University Press eBooks · doi:10.1017/9781316563205.013
Psychopharmakotherapie – klinisch-empirische Grundlagen
Volz, H., Kasper, S. F., & Möller, H. ‐. (2015) · Springer eBooks · doi:10.1007/978-3-642-45028-0_31-1
Baldessarini, R. J. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3710-9_2
van Heeringen, K. (2018) · Cambridge University Press eBooks · doi:10.1017/9781316563205.015
van Heeringen, K. (2018) · Cambridge University Press eBooks · doi:10.1017/9781316563205.001
García, C. I., Sáiz, P. A., García‐Portilla, M. P., & Bobes, J. (2016) · Springer eBooks · doi:10.1007/978-3-319-26282-6_26
Lethal Signals: The Molecular Neuroscience of Suicidal Behavior
van Heeringen, K. (2018) · Cambridge University Press eBooks · doi:10.1017/9781316563205.005
van Heeringen, K. (2018) · Cambridge University Press eBooks · doi:10.1017/9781316563205.012
Neuroleptic Malignant Syndrome associated with the use of LAI antipsychotics: how to avoid?
Pedro, M. P., Pedro, M. O. P., & Campos, S. (2019) · doi:10.26226/morressier.5d1a037657558b317a1406c5
Kadra-Scalzo, G., Ahn-Robbins, D., Bird, A., Broadbent, M. T. M., Chang, C., Pritchard, M., Shetty, H., Taylor, D. M., Hayes, R. D., & Stewart, R. J. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-051567 · Cited by 1
Pattern of use of clozapine in Spain. Variability and under-prescription
Sanz-Fuentenebro, F. J., Uriarte, J. J. U., Dalmau, P. B., Molina, V., & Arroyo, M. B. (2019) · Revista de Psiquiatría y Salud Mental (English Edition) · doi:10.1016/j.rpsmen.2018.02.012 · Cited by 9
Benkert, O., & Hippius, H. (2012) · Springer eBooks · doi:10.1007/978-3-642-29810-3_3 · Cited by 1
First-Generation Antipsychotics
Höschl, C. (2015) · Springer eBooks · doi:10.1007/978-3-642-36172-2_251
van Heeringen, K. (2018) · Cambridge University Press eBooks · doi:10.1017/9781316563205.014
First-Generation Antipsychotics
Höschl, C. (2014) · Springer eBooks · doi:10.1007/978-3-642-27772-6_251-2
Waters, H. C., Touya, M., Wee, S. N., Ng, M. S. W., Thadani, S., Surendran, S., Rentería, M. E., Rush, A. J., Patel, R., Sarkar, J., et al. (2022) · Current Medical Research and Opinion · doi:10.1080/03007995.2022.2148461
Chan, C. T., Verma, S. K., Subramaniam, M., Abdin, E., & Tay, J. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20043403 · Cited by 1
Foreman, D. M. (2024) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.230137 · Cited by 1
Schwärzler, F., & Frank, U. G. (2024) · Psychiatrische Praxis · doi:10.1055/a-2206-3781
Hietala, E., Solismaa, A., Lähteenvuo, M., Ahola‐Olli, A., Häkkinen, K., Suokas, K., Isometsä, E. T., Suvisaari, J., Kieseppä, T., Torniainen‐Holm, M., et al. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4884536
Self-citationSanzone, E. M., Kam, O., Sanzone, K., Bai, M. Y., Rodecker, N., Shad, M. U., Varghese, S. P., Barlati, S., Kirschner, M., Kooner, P., et al. (2024) · Journal of Psychiatric Practice · doi:10.1097/pra.0000000000000807
Forty years of research trends in long-acting injectable antipsychotics: A bibliometric analysis
Mert, A., & Mert, T. S. (2025) · Australasian Psychiatry · doi:10.1177/10398562251313929 · Cited by 2
Kane, J. M., Tohami, O., Franzenburg, K. R., Suett, M., Sharon, N. A., Wagner, A. M., Eshet, R., Harary, E., & Correll, C. U. (2025) · CNS Drugs · doi:10.1007/s40263-025-01240-1
Lehmann, P. (2013) · Springer eBooks · doi:10.1007/978-3-531-18784-6_8 · Cited by 1
Metadata
- Authors
- Tiihonen, J., Haukka, J., Taylor, M., Haddad, P. M., Patel, M. X., & Korhonen, P.
- Affiliations
- NHS Lothian (GB)
- Venue
- American Journal of Psychiatry
- Published
- 2011-06
- Volume
- 168
- Issue
- 6
- Pages
- 603-609
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2160096204
- Cited by
- 619
- References
- 28
- Citations by year
- 2026: 21 · 2025: 30 · 2024: 21 · 2023: 35 · 2022: 38 · 2021: 41 · 2020: 32 · 2019: 42 · 2018: 51 · 2017: 55 · 2016: 39 · 2015: 52 · 2014: 42 · 2013: 61 · 2012: 44
- FWCI
- 34.80
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (King's College London) (submittedVersion)
- STM:n Hallinnonalan avoin julkaisuarkisto (Julkari) (submittedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Social Sciences › Psychology › Clinical Psychology › Psychiatric care and mental health services
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Keywords
- schizophrenia, antipsychotic drugs, long-acting injectable antipsychotics, oral antipsychotics, hospital readmission, treatment discontinuation, clozapine, olanzapine, risperidone, mortality, medication adherence, first hospitalization
- MeSH terms
- Administration, Oral, Adolescent, Adult, Delayed-Action Preparations, Drug Implants, Finland, Hospitalization, Humans, Injections, Middle Aged, Patient Readmission, Schizophrenia, Antipsychotic Agents, Cohort Studies, Treatment Outcome, Secondary Prevention, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.